Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for renal outcomes in chronic kidney disease
2016-003896-24Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Primary composite renal and cardiovascular endpoint. Started Nov 2016; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-003896-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003896-24.